News 21.12.2024 Schlieren (Zurich), December 19, 2024 – LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LimmaTech’s multivalent toxoid vaccine candidate, LBT-SA7, designed to prevent skin and soft tissue...
News 13.12.2024 Zurich, Switzerland - 12.12.2024 Collaboration aims to accelerate clinical research and improve patient outcomes using advanced AI capabilities Neurimmune and AICURA Medical GmbH today announced a strategic collaboration to harness the latest breakthroughs in artificial intelligence (AI) for the development of therapeutics for the treatment of Alzheimer’s disease. The partnership will leverage advanced...
News 11.12.2024 The Wyss Zurich Regenerative Medicine Technologies Platform (Wyss Zurich RMTP) of the University of Zurich and ZüriPharm AG have entered into a strategic partnership to support and accelerate the translation of innovative therapies from research to clinical application. The aim of the close collaboration is to cover the entire life...
News 09.12.2024 CUTISS has received authorization from the European Medicines Agency (EMA) to commence the Phase 3 clinical trial for our lead product denovoSkin™ in adult & adolescent severe burn patients. Running across eight countries, including Belgium, France, Germany, Italy, the Netherlands, Poland, Portugal, and Spain, the Phase 3 confirmatory study will validate...
News 09.12.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of additional...